Baijin Life Science Clarifies Board and Committee Roles in Governance Update

An announcement from Affluent Partners Holdings ( (HK:1466) ) is now available.

Baijin Life Science Holdings has released an updated list of its directors and clarified the composition of its three key board committees. The announcement confirms the roles of executive, non-executive and independent non-executive directors, with Wong Siu Keung, Joe serving as chairman of the audit, remuneration and nomination committees, reinforcing the company’s corporate governance framework.

The detailed allocation of committee memberships, including independent directors as members across all three committees, underscores a focus on oversight of financial reporting, pay policies and board nominations. This structure is likely intended to align the company with prevailing governance standards for Hong Kong-listed issuers and provide greater transparency to investors about decision-making responsibilities at board level.

The most recent analyst rating on (HK:1466) stock is a Sell with a HK$0.49 price target. To see the full list of analyst forecasts on Affluent Partners Holdings stock, see the HK:1466 Stock Forecast page.

More about Affluent Partners Holdings

Baijin Life Science Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong under stock code 1466, operates in the life sciences sector. The company is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a conventional Hong Kong-listed corporate structure.

YTD Price Performance: 5.88%

Average Trading Volume: 334,567

Technical Sentiment Signal: Sell

Current Market Cap: HK$503.4M

See more insights into 1466 stock on TipRanks’ Stock Analysis page.